Cargando…

MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma

SIMPLE SUMMARY: Glioblastoma, the brain tumour with highest prevalence and lethality, exhibits a characteristic glycolytic phenotype with increased lactate production. Recently, we reported a MCT1 overexpression in GBMs tumours, being associated to tumour growth and aggressiveness. Thus, we aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miranda-Gonçalves, Vera, Gonçalves, Céline S., Granja, Sara, Vieira de Castro, Joana, Reis, Rui M., Costa, Bruno M., Baltazar, Fátima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306807/ https://www.ncbi.nlm.nih.gov/pubmed/34298681 http://dx.doi.org/10.3390/cancers13143468

Ejemplares similares

Hypoxia-mediated upregulation of MCT1 expression supports the glycolytic phenotype of glioblastomas
por: Miranda-Gonçalves, Vera, et al.
Publicado: (2016)

Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer
por: Pértega-Gomes, Nelma, et al.
Publicado: (2011)

Cadherin‐3 is a novel oncogenic biomarker with prognostic value in glioblastoma
por: Martins, Eduarda P., et al.
Publicado: (2022)

Impact of mesenchymal stem cells’ secretome on glioblastoma pathophysiology
por: Vieira de Castro, Joana, et al.
Publicado: (2017)

Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells
por: Miranda-Gonçalves, Vera, et al.
Publicado: (2017)

Exploiting the Complexities of Glioblastoma Stem Cells: Insights for Cancer Initiation and Therapeutic Targeting
por: Vieira de Castro, Joana, et al.
Publicado: (2020)

A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide
por: Pojo, Marta, et al.
Publicado: (2015)

WNT6 is a novel oncogenic prognostic biomarker in human glioblastoma
por: Gonçalves, Céline S., et al.
Publicado: (2018)

Intracellular Autofluorescence as a New Biomarker for Cancer Stem Cells in Glioblastoma
por: Vieira de Castro, Joana, et al.
Publicado: (2021)

Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization
por: Pinheiro, Céline, et al.
Publicado: (2014)

Chronic Stress Does Not Influence the Survival of Mouse Models of Glioblastoma
por: Lopes, Marta, et al.
Publicado: (2022)

Localization of MCT2 at peroxisomes is associated with malignant transformation in prostate cancer
por: Valença, Isabel, et al.
Publicado: (2015)

Glucose Metabolism Reprogramming in Bladder Cancer: Hexokinase 2 (HK2) as Prognostic Biomarker and Target for Bladder Cancer Therapy
por: Afonso, Julieta, et al.
Publicado: (2023)

Targeting lactate transport suppresses in vivo breast tumour growth
por: Morais-Santos, Filipa, et al.
Publicado: (2015)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Matteucinol combined with temozolomide inhibits glioblastoma proliferation, invasion, and progression: an in vitro, in silico, and in vivo study
por: Netto, J.B., et al.
Publicado: (2022)

Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: The CLEOPATRA Trial
por: Combs, Stephanie E, et al.
Publicado: (2010)

Outcomes of pediatric glioblastoma treated with adjuvant chemoradiation with temozolomide and correlation with prognostic factors
por: Mallick, Supriya, et al.
Publicado: (2015)

Monocarboxylate Transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer
por: Latif, Ayşe, et al.
Publicado: (2017)

Accelerated hyperfractionation plus temozolomide in glioblastoma
por: Kaul, David, et al.
Publicado: (2016)

Strategies of temozolomide in future glioblastoma treatment
por: Lee, Chooi Yeng
Publicado: (2017)

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
por: Saha, Dipongkor, et al.
Publicado: (2020)

Polymer–Temozolomide Conjugates as Therapeutics for Treating Glioblastoma
por: Ward, Sarah M., et al.
Publicado: (2018)

On optimal temozolomide scheduling for slowly growing glioblastomas
por: Segura-Collar, Berta, et al.
Publicado: (2022)

Obstacles to Glioblastoma Treatment Two Decades after Temozolomide
por: Cruz, João Victor Roza, et al.
Publicado: (2022)

Poor-Prognosis Patients Affected by Glioblastoma: Retrospective Study of Hypofractionated Radiotherapy with Simultaneous Integrated Boost and Concurrent/Adjuvant Temozolomide
por: Gregucci, Fabiana, et al.
Publicado: (2021)

Dovitinib enhances temozolomide efficacy in glioblastoma cells
por: Thanasupawat, Thatchawan, et al.
Publicado: (2017)

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
por: JIAPAER, Shabierjiang, et al.
Publicado: (2018)

Considering the Experimental Use of Temozolomide in Glioblastoma Research
por: Herbener, Verena J., et al.
Publicado: (2020)

Repurposing Penfluridol in Combination with Temozolomide for the Treatment of Glioblastoma
por: Kim, Hyungsin, et al.
Publicado: (2019)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

Transferrin-Conjugated PLGA Nanoparticles for Co-Delivery of Temozolomide and Bortezomib to Glioblastoma Cells
por: Ramalho, Maria João, et al.
Publicado: (2023)

Natural Autoimmunity to the Thyroid Hormone Monocarboxylate Transporters MCT8 and MCT10
por: Porst, Theresa, et al.
Publicado: (2021)

Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells
por: Beltzig, Lea, et al.
Publicado: (2022)

Evaluation of MCT1, MCT4 and CD147 Genes in Peripheral Blood Cells of Breast Cancer Patients and Their Potential Use as Diagnostic and Prognostic Markers
por: Luz, Maria Cláudia de B., et al.
Publicado: (2017)

Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide
por: Sun, Stella, et al.
Publicado: (2012)

Inhibition of Hypothalamic MCT4 and MCT1–MCT4 Expressions Affects Food Intake and Alters Orexigenic and Anorexigenic Neuropeptide Expressions
por: Elizondo-Vega, Roberto, et al.
Publicado: (2019)

Transcriptional profiling of HOXA9-regulated genes in human glioblastoma cell models
por: Gonçalves, Céline S., et al.
Publicado: (2015)

Glucose Influences the Response of Glioblastoma Cells to Temozolomide and Dexamethasone
por: Bielecka-Wajdman, Anna M, et al.
Publicado: (2022)

A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_7prmg1nrppats1g1vm8akbimbr